Stocks / Stock overview

GeneDx Holdings Corp. (WGS)

$86.34-3.26%Aft $87.00 (+0.77%)Market cap $2.57B

NasdaqGS · Price as of · Nasdaq Real Time Price

Stock Scorer
C48/100
  • Profitability0/20

    Losing money: $-116.4M net income over the last four reported quarters. Revenue over the last four reported quarters was $454.4M, up 19% from $381.1M the year before.

  • Insider buying vs selling20/20

    Insiders are net buyers: 27 open-market buys worth $93.1M vs 12 sells worth $1.3M across the last 20 Form 4 filings.

  • Dilution and offerings6/15

    Share count up 3.8% in a year plus 1 offering-related filing. Real dilution. One nuance: offerings raise cash that can fund real growth. The score docks the certain near-term dilution; if the spending pays off, it shows up later in the profitability component.

See the full breakdown
Analyst consensus
Rated$90.44
  • Analysts9
  • Implied upside+4.8%
  • Target range$74.00 to $103.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
October 27, 2026date estimated
  • EPS expected$0.07 -85%
  • A year ago$0.49
  • Revenue expected$123.0M +5.3%
  • Estimate range$0.07 to $0.08
Consensus of 8 analysts for the quarter ending September 30, 2026. Estimates are what Wall Street expects, not our forecast.
Source: Yahoo Finance earnings calendar
WGS past month+25.2%
WGS closed at $86.34 on Aug 28, up 25.2% since Jul 30.$86.34$91.32$59.52Jul 30Aug 28
Close 20-day average 50-day average 200-day average

WGS closed at $86.34 on Aug 28, up 25.2% since Jul 30. Chart read: price above both the 50-day and 200-day moving averages; the 50-day is below the 200-day (downtrend structure); trading at 39% of the 52-week range ($34.51 to $167.51).

SEC filings

Source: SEC EDGARLatest filed

FormFiledDescription
SCHEDULE 13GAugust 11, 2026View on EDGAR
SCHEDULE 13G/AAugust 7, 2026View on EDGAR
10-QAugust 3, 202610-Q
8-KAugust 3, 20268-K
SCHEDULE 13GJuly 28, 2026View on EDGAR
25-NSEJuly 21, 2026View on EDGAR
4July 1, 2026View on EDGAR
4June 23, 2026View on EDGAR
All SEC filings

GeneDx news

Cathie Wood's ARK tripled its GeneDx (WGS) stake in 10 months. It now owns 5.33% of the company.
News

Cathie Wood's ARK tripled its GeneDx (WGS) stake in 10 months. It now owns 5.33% of the company.

ARK's GeneDx (WGS) position has grown every quarter for ten months straight, through an 81 percent stock crash and most of the recovery back. The fund just crossed 5 percent ownership.

Aug 7, 2026

Frequently asked questions

When does WGS report earnings?

GeneDx Holdings Corp. (WGS) is scheduled to report quarterly results on October 27, 2026 (estimated). The 8-analyst consensus is $0.07 per share on revenue of $123.0M for the quarter ending September 30, 2026, against $0.49 and $116.7M a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.

What do analysts expect for WGS?

9 analysts cover GeneDx Holdings Corp. (WGS). No consensus rating has been published. The average price target is $90.44, in a range of $74.00 to $103.00.

Are insiders buying or selling WGS?

We have no qualifying Form 4 insider purchases or sales on record for GeneDx Holdings Corp. (WGS). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Where can I see WGS SEC filings?

Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G filed August 11, 2026.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.